Ischemia modified albumin: Is this marker of ischemia ready for prime time use?

Hellenic Journal of Cardiology

Volumn 49, Issue 4, 2008, Pages 260-266

  Sbarouni, Eftihia ^a,c   Georgiadou, Panagiota ^a   Kremastinos, Dimitrios Th ^b   Voudris, Vasilios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Ischemia modified albumin; Myocardial ischemia and injury

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATINE KINASE MB; ISCHEMIA MODIFIED ALBUMIN; ISOPROSTANE; LACTIC ACID; MYOGLOBIN; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; BINDING SITE; CHEMICAL BINDING; CLINICAL EXAMINATION; CLINICAL TRIAL; ELECTROCARDIOGRAM; EXERCISE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; LACTIC ACIDOSIS; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CATHETER ABLATION; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 54549090075     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001; 104: 365-372.
2. Toutouzas K, Stefanadis C. Advances in vulnerable plaque detection and treatment: how far have we gone? Hellenic J Cardiol. 2006; 47: 129-131.
3. Apple FS, Wu AHB, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005; 51: 810-824.
4. Tsakiris AK, Marnelos PG, Nearchou NS, Papadakis JE, Karatzis EN, Skoufas PD. The influence of thrombolytic therapy on C-reactive protein in ST-segment elevation acute myocardial infarction. Hellenic J Cardiol. 2006; 47: 218-222.
5. Bar-Or D, Lau E, Winkler JV. Novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J Emerg Med. 2000; 19: 311-315.
6. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. Eur J Biochem. 2001; 268: 42-47.
7. Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem. 1995; 227: 524-528.
8. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006; 92: 113-114.
9. Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J. 2001; 141: 985-991.
10. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation. 2003; 107: 2403-2405.
11. Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med. 2004; 35: 1-5.
12. Abboud H, Labreuche J, Meseguer E, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis. 2007; 23: 216-220.
13. Prefumo F, Gaze DC, Papageorghiou AT, Collinson PO, Thilaganathan B. First trimester maternal serum ischaemia-modified albumin: a marker of hypoxia-ischaemia-driven early trophoblast development. Hum Reprod. 2007; 22: 2029-2032.
14. Gaze DC, Crompton L, Collinson P. Ischemia-modified albumin concentrations should be interpreted with caution in patients with low serum albumin concentrations. Med Princ Pract. 2006; 15: 322-324.
15. Zapico-Muñiz E, Santaló-Bel M, Mercé-Muntañola J, Montiel JA, Martínez-Rubio A, Ordóñez-Llanos J. Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem. 2004; 50: 1063-1065.
16. Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003; 49: 581-585.
17. Quiles J, Roy D, Gaze D, et al. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol. 2003; 92: 322-324.
18. Garrido IP, Roy D, Calvino R, et al. Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without collaterals. Am J Cardiol. 2004; 93: 88-90.
19. Sinha MK, Vazquez JM, Calvino R, Gaze DC, Collinson PO, Kaski JC. Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart. 2006; 92: 1852-1853.
20. Cho DK, Choi JO, Kim SH, et al. Ischemia-modified albumin is a highly sensitive serum marker of transient myocardial ischemia induced by coronary vasospasm. Coron Artery Dis. 2007; 18: 83-87.
21. Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicentric study. Clin Chem. 2001; 47: 464-470.
22. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski J-C. Role of ischemia modified albumin a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emerg Med J. 2004; 21: 29-34.
23. Keating L, Benger JR, Beetham R, et al. The PRIMA study: presentation ischaemia-modified albumin in the emergency department. Emerg Med J. 2006; 23: 764-768.
24. Collinson PO, Gaze DC, Bainbridge K, et al. Utility of admission cardiac troponin and "ischemia modified albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J. 2006; 23: 256-261.
25. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. 2006; 152: 253-262.
26. Roy D, Kaski JC. High-risk acute coronary syndrome patients and cardiac biomarkers in the emergency department: any role for new biomarkers of myocardial ischaemia? Eur Heart J. 2007; 28: 2297.
27. Shave R, George K, Gaze D. The influence of exercise upon cardiac biomarkers: a practical guide for clinicians and scientists. Curr Med Chem. 2007; 14: 1427-1436.
28. Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem. 2002; 48: 1097-1100.
29. Middleton N, Shave R, George K, et al. Novel application of flow propagation velocity and ischaemia-modified albumin in analysis of postexercise cardiac function in man. Exp Physiol. 2006;91:511-519.
30. Falkensammer J, Stojakovic T, Huber K, et al. Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia. Clin Chem Lab Med. 2007; 45: 535-540.
31. Roy D, Quiles J, Sharma R, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clinical Chemistry. 2004; 50: 1656-1660.
32. Van der Zee PM, Verberne HJ, Straalen JP, et al. Ischemia-modified albumin measurements in symptom-limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischemia. Clin Chem. 2005; 51: 1744-1746.
33. Sbarouni E, Georgiadou P, Theodorakis GN, Kremastinos DT. Ischemia-modified albumin in relation to exercise stress testing. J Am Coll Cardiol. 2006; 48: 2482-2484.
34. Kurz K, Voelker R, Zdunek D, et al. Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol. 2007; 96: 152-159.
35. Rao SP, Miller S, Rosenbaum R, Lakier JB. Cardiac troponin I and cardiac enzymes after electrophysiologic studies, ablations, and defibrillator implantations. Am J Cardiol. 1999; 84: 470.
36. Sbarouni E, Georgiadou P, Panagiotakos D, Livanis EG, Theodorakis GN, Kremastinos DT. Ischaemia modified albumin in radiofrequency catheter ablation. Europace. 2007; 9: 127-129.
37. Roy D, Quiles J, Sinha M, et al. Effect of radiofrequency catheter ablation on the biochemical marker ischemia-modified albumin. Am J Cardiol. 2004; 94: 234-236.
38. Roy D, Quiles J, Sinha M, et al. Effect of direct-current cardioversion on ischemia-modified albumin in patients with atrial fibrillation. Am J Cardiol. 2004; 93: 366-368.
39. Sbarouni E, Georgiadou P, Panagiotakos D, Livanis E, Theodorakis GN, Kremastinos DT. The ischemia-modified albumin in relation to pacemaker and defibrillator implantation. Pacing Clin Electrophysiol. 2008; 31: 83-87.
40. Turedi S, Gunduz A, Mentese A, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med. 2007; 25: 770-773.
41. Worster A, Devereaux PJ, Heels-Ansdell D, et al. Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. CMAJ. 2005; 172: 1685-1690. 42. Dusek J, Stásek J, Tichý M, et al. Prognostic significance of ischemia modified albumin after percutaneous coronary intervention. Clin Chim Acta. 2006; 367: 77-80.
42. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC. Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Clin Chim Acta. 2008; 388: 196-199.
43. Aparci M, Kardesoglu E, Ozmen N, et al. Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome. Coron Artery Dis. 2007; 18: 367-373.